(Bloomberg) — Pfizer Inc.’s $48 billion gain in market value since late March, egged on by optimism for a successful Covid-19 vaccine, may soon hit a wall.Among the top three developers, Pfizer may be first to reveal late-stage results from its trials of tens of thousands of people with partner BioNTech SE. And if history is any guide, the shares may eventually head lower no matter what the data show.Goldman Sachs Group Inc. calls it the vaccine trade — where daytrading generalist investors pile into stocks developing treatments and vaccines for the disease, then flee shortly after results or updates …read more
Source:: Yahoo Finance
